drugset / Trial / NCT06629389

Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

NCT06629389

Phase 2 Recruiting 88 enrolled Laboratorio Elea Phoenix S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by clinical motor and non-motor symptoms. Knowing the potential benefits has led to the use of cannabis as an alternative therapy.

Timeline

Start
2024-11-28
Primary completion
2025-11
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cannabidiol Other / unclassified 100 mg/ml
Comparator Cannabidiol Other / unclassified 300 mg/ml
Comparator Cannabidiol Other / unclassified 400 mg/ml

Indications